Translational Platforms of Obesity, Dysmetabolism, Diabetes, and Complications
Presented by Dr. Jim Wang, Senior Vice President of Cardiovascular and Metabolic Disease Research and President of CrownBio Indiana and Louisiana
A key challenge in preclinical obesity, dysmetabolism, and diabetes studies is the lack of translational platforms that model the various aspects of disease progression and associated complications. Conventional rodent models of obesity do not recapitulate human disease, with more translational models required.
In this webinar, Dr. Wang presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. He’ll discuss next generation polygenic rodent models as well as spontaneously dysmetabolic and diabetic nonhuman primates.
Explore the disease features, progression, and complications of these highly translational preclinical models, and how they are used to predict the efficacy and safety of anti-diabetic and NAFLD/NASH therapies in humans.
Watch This Webinar To Learn How To:
- Use translational rodent and non-human primate models to study obesity, dysmetabolism, diabetes, and related complications
- Exploit the advantages of next generation polygenic rodent models (MS-NASH (formerly called FATZO) mouse and ZDSD rat) with intact leptin pathways which more closely recapitulate human disease
- Optimally implement spontaneously diabetic NHPs in modeling human metabolic disease
- Model human-relevant disease progression and complications related to obesity and diabetes, including NAFLD/NASH, cardiac dysfunction, and nephropathy in translational rodents and NHPs
- Monitor liver disease in obese NHPs using a unique non-invasive ultrasound technique
- Utilize these translational models to assess the efficacy and safety of anti-diabetes and NAFLD/NASH therapeutics, which show human disease-relevant response to SoC agents
Watch The Webinar Now!
About The Presenter:
Dr. Jim Wang is the Senior Vice President of Cardiovascular and Metabolic Disease Research and President of CrownBio Indiana and Louisiana. He started his academic career as a postdoctoral researcher at Boston University in 1987, and in 1992 became an assistant professor at the University of Tennessee in Memphis where he worked until 1996. Dr. Wang has worked in several major pharma companies (GSK, Roche, Schering/Bayer AG) as a Scientist, Senior Scientist, and Principle Scientist from 1990 to 2008 and in a start-up biotech (Arete Therapeutics, Inc.) as a Director of Pharmacology from 2008 to 2009.
In 2010, Jim joined CrownBio as the Head of CVMD Research. He has authored nearly 100 publications between research articles, invited reviews, and book chapters, and has submitted patent applications in the areas of diabetes and metabolic diseases, heart and renal failure, hypertension, thrombosis, hemophilia, atherosclerosis and dyslipidemia, hemodynamics, pharmacokinetics and pharmacodynamics, safety pharmacology, etc. Dr. Wang has been involved in all stages of pharmaceutical R&D, from early stage target discovery and validation, to compound (large and small molecules) discovery, selection and profiling, IND filing, and clinical trials in Phase I and II.